Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors

American Journal of Veterinary Research

Volumn 65, Issue 11, 2004, Pages 1502-1507

  Bailey, Dennis B ^a   Rassnick, Kenneth M ^a   Erb, Hollis N ^a   Dykes, Nathan L ^a   Hoopes, P Jack ^b   Page, Rodney L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GREEN FLUORESCENT PROTEIN; PENTETATE TECHNETIUM TC 99M;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD CELL COUNT; BODY SURFACE; BODY WEIGHT; BONE MARROW TOXICITY; CAT DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; INDIVIDUALIZATION; MALE; MONITORING; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; AREA UNDER CURVE; BLOOD CELL COUNT; BLOOD PLATELETS; CARBOPLATIN; CAT DISEASES; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; NEOPLASMS; NEUTROPHILS; PLATINUM; REGRESSION ANALYSIS; SPECTROPHOTOMETRY, ATOMIC; TECHNETIUM TC 99M PENTETATE;

ANIMALIA; FELIS CATUS; GLOMERULUS;

EID: 9444220180     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.1502     Document Type: Article

References (35)

1. Théon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205-210.
2. Fry DR, Snelling SR, Beck C. Partial remission of an inoperable extraskeletal osteosarcoma in association with carboplatin in a cat. Aust Vet Pract 2003;33:103-104.
3. Hahn KA, McEntee MF, Daniel GB, et al. Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am J Vet Res 1997;58:677-679.
4. Calvert AH, Harland SJ, Newell DR, et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 1985;12(suppl A):51-57.
5. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982;9:140-147.
6. Curt GA, Grygiel JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res 1983;43:4470-4473.
7. Koeller JM, Trump DL, Tutsch KD, et al. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 1986;57:222-225.
8. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-5438.
9. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985;45:6502-6506.
10. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
11. Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984; 44:1693-1697.
12. Gibaldi M. Introduction to pharmacokinetics. Biopharmaceutics and clinical pharmacokinetics. 4th ed. Philadelphia: Lea & Febiger, 1991;
13. Alberts DS, Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 1998; 3:15-34.
14. Donahue A, McCune JS, Faucette S, et al. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol 2001;47:373-379.
15. Rubin SI. Chronic renal failure and its management and nephrolithiasis. Vet Clin North Am Small Anim Pract 1997; 27:1331-1354.
16. Lund EM, Armstrong PJ, Kirk CA, et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc 1999; 14:1336-1341.
17. Finco DR, Duncan JR. Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: a study of 111 cases and a review of related literature. J Am Vet Med Assoc 1976;168:593-601.
18. Browner WS, Newman TB, Cummings SR, et al. Estimating sample size and power. In: Hulley SB, Cummings SR, Browner WS, et al, eds. Designing clinical research. 2nd ed. New York: Lippincott Williams & Wilkins, 2001;65-91.
19. Rogers KS, Komkov A, Brown SA, et al. Comparison of four methods of estimating glomerular filtration rate in cats. Am J Vet Res 1991;52:961-964.
20. 131I-orthoiodohippurate plasma clearance in dogs and cats. J Vet Intern Med 2001;15:200-208.
21. 2). In: Veterinary drug handbook. 4th ed. Ames, Iowa: Iowa State Press, 2002;903.
22. Rassnick KM, Gieger TL, Williams LE, et al. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med 2001; 15:196-199.
23. Chu E, DeVita VT. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001;289-306.
24. Lulich JP, Osborne CA, O'Brien TD, et al. Feline renal failure: questions, answers, questions. Compend Contin Educ Pract Vet 1992;14:127-153.
25. Gibaldi M. Drug disposition - distribution. In: Biopharmaceutics and clinical pharmacokinetics. 4th ed. Philadelphia: Lea & Febiger, 1991;187-233.
26. Siddik ZH, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925-1932.
27. Siddik ZH, Jones M, Boxall FE, et al. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 1988;21:19-24.
28. Daley-Yates PT, McBrien DC. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Biochem Pharmacol 1985;34:1423-1428.
29. van Hennik MB, van der Vijgh WJ, Klein I, et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 1987;47:6297-6301.
30. Sorensen BT, Stromgren A, Jakobsen P, et al. Renal handling of carboplatin. Cancer Chemother Pharmacol 1992;30:317-320.
31. Miyamoto K. Evaluation of single-injection method of inulin and creatinine as a renal function test in normal cats. J Vet Med Sci 1998;60:327-332.
32. Finco DR. Evaluation of renal functions. In: Osborne CA, Finco DR, eds. Canine and feline nephrology. Baltimore: The Williams & Wilkins Co, 1995;216-229.
33. Barthez PY, Chew DJ, DiBartola SP. Effect of sample number and time on determination of plasma clearance of technetium Tc 99m penterate and orthoiodohippurate sodium I 131 in dogs and cats. Am J Vet Res 2000;61:280-285.
34. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-580.
35. Finco DR. Applied physiology of the kidney In: Osborne CA, Finco DR, eds. Canine and feline nephrology. Baltimore: The Williams & Wilkins Co, 1995;29-46.